Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 424  |  Browse by Industry: Previous - Next | All     monitor keywords
Recent  |  14: Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
08/07/2014 > 255 patent applications in 116 patent subcategories.

20140219913 - Dual specific binding proteins having a receptor sequence: Engineered multispecific binding proteins that bind at least one ligand for a receptor are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.... Agent: Abbvie, Inc.

20140219912 - Dual variable domain immunoglobulins and uses thereof: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.... Agent: Abbvie, Inc.

20140219914 - Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24... Agent: Immunomedics, Inc.

20140219915 - Cryptate compounds: Disclosed herein is a method for coupling a first compound having the formula (I) with a second compound that contains a carbonyl group. Also disclosed herein are compounds that can be formed by this method, and uses for such compounds.... Agent: The Australian National University

20140219916 - Method and compound for treatment of cancer using phosphorous-32 labeled dna: This invention provides a combination of a DNA strand/fragment and isotope therapy that is applied to a cancerous tissue to selectively kill cancer cells with minimal negative effects on surrounding non-cancerous cells. Linear DNA fragments with labeled isotope are able to be absorbed by the tumor cells and bind the... Agent:

20140219917 - Oligosaccharide conjugates for targeting bacteria and uses related thereto: This disclosure relates to conjugates for targeting bacteria and related uses. In certain embodiments, the disclosure relates to methods of transferring a molecule of interest into bacteria comprising mixing bacteria with a non-naturally occurring conjugate under conditions such that the conjugate is transported across the bacterial cell wall. Typically, the... Agent: Georgia Tech Research Corporation

20140219919 - Il-11r binding proteins and uses thereof: The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (IL-11) receptor alpha (IL-11Rα) and uses thereof, e.g., in therapy.... Agent: Csl Limited

20140219920 - Immunocytokine combination therapy: Methods and compositions for treating tumours, especially skin tumours, by locally administering single doses of tumour necrosis factor alpha (TNFα) and interleukin-2 (IL2) at the tumour site, where the TNFα and IL2 are delivered as immunoconjugates comprising an antibody targeted to a splice isoform of an extracellular matrix component such... Agent: Philogen S.p.a.

20140219918 - Peptide: The present invention provides a foot-and-mouth diseases virus (FMDV) VP1 capsid protein which comprises an entity of interest (EOI). The EOI sequence may, for example, be an epitope tag, an immunomodulatory molecule or a target molecule. The present invention also provides an FMDV vaccine which comprises such a VP1 capsid... Agent: The Pirbright Institute

20140219921 - Immunomodulating compositions and methods: The disclosure provides compositions in the form of cells exhibiting the phenotype of a mesenchymal stem cell and uses of such cells in the preparation of medicament and the treatment of an allergic reaction in an asthmatic subject. Also provided are methods of inducing tolerance to an allergen in an... Agent: Rutgers, The State University Of New Jersey

20140219926 - Biodegradable iron oxide nanoparticle gel for tumor bed therapy: A biodegradable iron oxide nanoparticle gel for hyperthermia treatment of cancer includes a polysaccharide-based carrier matrix and starch-coated iron oxide nanoparticles. The gel has sufficient deformability to integrate into a diffuse tumor site, adheres to tissue and has sufficient mechanical properties to remain in place during hyperthermia treatment. The gel... Agent: The Trustees Of Dartmouth College

20140219923 - Biodegradable compositions suitable for controlled release: A special class of drug-depot forming triblock copolymers which are very suitable for the loading, containment and releasing of sensitive drugs such as proteins from biodegradable, injectable drug depots. How to visualize these depots for various imaging related purposes is described. A composition comprising a tri-block copolymer according to formula... Agent: Ingell Technologies Holding B.v.

20140219924 - Medical tissue-marker and manufacturing method for the same: The present invention is to provide a medical tissue-marker which enables the identification of a location even from the outside of an organ, can remain topical over a long period, and enables the easy identification of a marked location within the whole organ; also to provide a manufacturing method for... Agent:

20140219922 - Use of scintillator-based nanoparticles for in vivo control of light-sensitive bioactive molecules: The method for remote, non-invasive in vivo control of the activation of light-sensitive bioactive molecules for the purpose of research or therapy is based on delivering to the required site of the body of nanoparticles along with said light-sensitive bioactive molecules. Nanoparticles' core is made from scintillator material that absorbs... Agent:

20140219925 - Polymer particles or nano-vectors and use thereof as a drug and/or diagnostic agent: Novel polymer nanovectors or particles and use thereof as medication and/or diagnostic agents.... Agent: Inserm (institut National De La Sante Et De La Recherche Medicale)

20140219927 - Hair fixative compositions: A hair fixative composition includes a hair fixative polymer and a solvent system where the solvent system includes ethanol and another non-aqueous solvent in a weight ratio in a range of about 80:20 to about 20:80 of ethanol to the other non-aqueous solvent, and optionally a propellant.... Agent: Akzo Nobel Chemicals International B.v.

20140219929 - Oleaginous pharmaceutical and cosmetic foam: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein... Agent: Foamix Ltd.

20140219928 - Topical oily foam compositions: Topical alcohol-free thermo labile oily foam composition comprising (i) at least one active pharmaceutical ingredient or ectoparasitic active ingredient; (ii) at least about 20% w/w of at least one lipophilic component; (iii) at least about 10% w/w of at least one non-ionic surfactant; (iv) at least about 0.5% w/w of... Agent:

20140219930 - Cooling enhancing compositions: The following invention relates to a taste enhancer and a method of enhancing taste. The invention relates the use of a cooling enhancing composition which provides cooling enhancement when combined with other cooling compounds.... Agent: International Flavors & Fragrances Inc.

20140219931 - P-menthane-3,8-diol isomer mixture, cooling sensation composition comprising the same, and product comprising the cooling sensation composition: The present invention relates to a p-menthane-3,8-diol isomer mixture 50% by mass or more of which is constituted of (1S)-isomers and a cooling sensation composition containing this mixture. The present invention also relates to a flavor and/or fragrance composition, food, beverage, cosmetic, daily use product, oral cavity composition, or pharmaceutical... Agent: Takasago International Corporation

20140219932 - Enamel protectant and repair toothpaste: Substantially aqueous-free, enamel protectant and enamel repair toothpastes containing: stannous fluoride, calcium and a substantivity agent comprising: an emulsion of polydimethylsiloxane in a nonionic surfactant, wherein: (a) substantivity of said stannous fluoride and calcium into biofilm present on enamel is enhanced through calcium binding shifting from bidentate to monodentate in... Agent: Premier Dental Products Company

20140219933 - Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease: The present document describes methods of use of photo activated compositions for oral disinfection and/or treatments which comprise at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmacologically acceptable... Agent: Klox Technologies Inc.

20140219934 - Botanical tooth whitener composition and method for treating discolored or stained teeth: A botanical tooth whitener composition comprises a quantity of camellia oil, a flavoring, and a thickening agent. The composition is comprised of natural substances and is generally free of chemical additives commonly found in related products. The composition may be used to reduce tooth discoloration or staining by brightening the... Agent:

20140219936 - Oil-in-water emulsion having improved sensory properties: An oil-in-water emulsion includes, for 100 wt % thereof: a) 0.1 to 10 wt % of an emulsifying system including, for 100 wt % thereof: (i) 5 to 95 wt % of the mixture of the reaction products of a reducing sugar and 1,12-octadecanediol essentially consisting of hydroxyl-octadecyl polyglycosides of... Agent: Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic

20140219935 - Topical bioadhesive formulations: The present invention relates to topical bioadhesive formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is... Agent: Camurus Ab

20140219937 - Topical sunscreen compositions: Substantially anhydrous compositions including at least 10% by weight of a C2 or C3 mono-alcohol, a solid, organic UV-filter dissolved therein; and an oil portion including one or more oils, the oil portion having an interfacial tension with water of greater than 9 and less than 32.5, where the composition... Agent: Johnson & Johnson Consumer Companies, Inc.

20140219938 - Sunscreens: The present invention relates to a composition for topical application in the form of an oil-in-water (O/W) emulsion comprising in a physiologically acceptable medium at least a dibenzoylmethane derivative, an amino substituted hydroxybenzophenone derivative and a benzotriazol derivative.... Agent: DsmIPAssets B.v.

20140219939 - Liquid skin-conditioning composition: The present invention provides an external-use liquid skin-conditioning composition that not only reduces the sticky and friction sensations caused by the inclusion of tranexamic acid, but also has a rich body without feeling slimy and softens the skin after use. The composition comprises (A) 0.5 to 5 mass % of... Agent: Shiseido Company, Ltd.

20140219940 - Skin-lightening agent: Provided are a very safe skin whitening agent, melanin production inhibitor, and dopa oxidase activity inhibitor. Use of kitsunenomago or an organic solvent extract thereof to inhibit the dopa oxidase activity.... Agent: Kao Corporation

20140219941 - Cosmetic powder coated with alginic acid and methods of making the same: The present disclosure relates generally to cosmetic powders having improved dispersibility, feel, and stability in which the powders are surface modified with at least one alginic acid, or salt form thereof. The powders may be used in cosmetic compositions such as a powder foundation skin toner, skin lotion, or body... Agent: U.s. Cosmetic Corporation

20140219943 - Complex for improvement of distribution and retention of fragrances into keratinous matter, uses, cosmetic product and method for improvement of distribution and retention of fragrances into keratinous matter: The present invention refers to a complex for the improvement of distribution and retention of fragrances into keratinous matter comprising (a) C10-C18 alkyl pyrrolidone, (b) at least one polyol compound and (c) at least one fatty alcohol, as well as uses, products, and related methods. The complex of the present... Agent: Isp Investments Inc.

20140219942 - Sunscreens: The present invention relates to a composition for topical application comprising at least a benzotriazol derivative and a cosmetic solvent selected from the group consisting of benzoate solvents such as phenethyl benzoate, dimethyl capramide and diethylhexyl 2,6-naphthalate. Furthermore, the invention relates to the use of specific benzotriazol derivatives to mask... Agent: DsmIPAssets B.v.

20140219945 - Cosmetic composition comprising at least one particular amphoteric polymer and at least one particular conditioning agent: Cosmetic composition comprising at least one particular amphoteric polymer and at least one particular conditioning agent The present invention relates to a cosmetic composition comprising: a)—one or more amphoteric polymers comprising a repetition of: (i) one or more units obtained from a monomer of (meth)acrylamide type, (ii) one or more... Agent: L'oreal

20140219946 - Use of microemulsions in cosmetic cleaning compositions: s

20140219944 - Method for forming volumizing, fixative, and conditioning particles for fine hair: A method for forming a large particle complex comprising the steps of combining a hydrolyzed corn starch polymer, a starch/cellulose polymer, a hydrogenated phospholipid, and gum arabic in a cosmetically acceptable carrier to form a premix composition; heating said premix to about 85° C. for about 15 minutes; and cooling... Agent:

20140219948 - Deodorant spray: A deodorant comprises triethyl citrate, zinc glycinate, and water. The deodorant has a pH of 5.5 to 6.5.... Agent: C.b. Fleet Company Inc.

20140219947 - Scent and ultra-violet elimination formulation: An odor and ultra-violet light elimination formulation for application to hunting garments and equipment. The formulation has an ultra-violet light inhibitor which absorbs ultra-violet light emissions. The formulation also has a polymer providing a protective layer against odor causing molecules. And the formulation has a quaternary ammonium for eliminating odors... Agent:

20140219949 - Pharmaceutical compositions comprising iodine and steroid and uses thereof for sinus diseases: The present invention provides pharmaceutical compositions comprising an iodine-containing compound and a steroid, useful for treating a clinical symptom in a patient's airway (e.g., nose, lung, and sinus), as well as methods for using the same.... Agent: Jiangsu Deda Pharmaceuticals Co. Ltd

20140219950 - Enhanced transport using membrane disruptive agents: Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure... Agent: University Of Washington

20140219951 - Amido-amine dendrimer compositions: Amide compounds, amide polymers and compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, the amide polymers may be amido-amine dendrimers that may be formed via a series of iterative reactions.... Agent: Genzyme Corporation

20140219953 - Adhesive cell tissue gels: Described herein is a cell tissue gel cross-linked with a cross-linking agent, and a quenching agent bound to a reactive group of the cross-linking agent.... Agent: National Cheng Kung University

20140219954 - Dry powder formulations of organic macromolecules: The present invention relates to methods for making a stabilized powder formulation for inhalation comprising a macromolecule in lyophilized form, a crystalline carrier material, and magnesium stearate.... Agent:

20140219952 - Methods of treatment using stem cell mobilizers: The present invention relates to the field of stem cells. In one aspect, the present invention provides methods of treating a subject with acute liver injury comprising administering to the subject a therapeutically effective amount of at least one stem cell mobilizer. In particular embodiments, the subject is treated with... Agent: The Johns Hopkins University

20140219955 - Fusion molecules and il-15 variants: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making thesuch proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.... Agent: Altor Bioscience Corporation

20140219956 - Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer: Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (P2PDox) with antibodies or antigen-binding fragments thereof (ADCs), with targetable construct peptides or with other targeting molecules that are capable of delivering the P2PDox to a targeted cell, tissue or pathogen. Once delivered to the target cell,... Agent: Immunomedics, Inc.

20140219957 - Methods and compositions for the treatment of immune disorders: The invention features methods of treating an immune disorder characterized by elevated Pin1 marker levels in a subject by administering a retinoic acid compound. Additionally, the invention features methods of treating immune disorders (e.g., immune disorders characterized by elevated Pin1 marker levels) by administering a retinoic acid compound in combination... Agent: Beth Israel Deaconess Medical Center, Inc.

20140219958 - 5, 6-d2 uridine nucleoside/tide derivatives: e

20140219959 - Human fusion proteins comprising interferons and targeted modified ubiquitin proteins: The present invention relates to fusion proteins in which a pharmaceutically active component is fused to an antibody mimetic. The invention specifically concerns fusion proteins comprising interferons or biologically active muteins thereof and modified hetero-dimeric ubiquitin proteins as specific targeting domain. The invention further relates to these fusion proteins for... Agent: Scil Proteins Gmbh

20140219960 - Novel composition for preventing or treating hepatitis c virus, regulating phosphorylation of replicase: The present invention relates a novel composition for preventing or treating hepatitis C virus, regulating the phosphorylation of a replicase. More specifically, it is possible to prevent or treat hepatitis C using a novel PRK2 inhibitor discovered through structure modeling, and to prevent or treat hepatitis C, particularly, interferon-insensitive hepatitis... Agent: Industry-academic Cooperation Foundation, Yonsei University

20140219961 - Pharmaceutical composition for treating cancer, comprising interferon alpha conjugate: A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the... Agent: Hanmi Science Co., Ltd.

20140219963 - Extracellular matrix-derived gels and related methods: Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher

20140219962 - Porous chitosan scaffolds and related methods: Porous chitosan scaffold having high mechanical strength, methods for making the porous chitosan scaffold, and method for using the porous chitosan scaffold.... Agent: University Of Washington Through Its Center For Commercialization

20140219965 - Controlling appetite, promoting weight loss, reducing body fat, and/or improving glucose tolerance: A method for treating obesity, insulin sensitivity, and related conditions involves administering to the subject a bacterium for overexpressing a N-acyl-phosphatidylethanolamine (NAPE) and/or a N-acylethanolamine (NAE). A composition includes a bacterium for overexpressing a N-acyl-phosphatidylethanolamine (NAPE) and/or a N-acylethanolamine (NAE); and an ingestible vehicle in which the bacterium is provided.... Agent: Vanderbilt University

20140219964 - Methods for inducing cardiomyocyte proliferation: Methods for inducing cardiomyocyte proliferation, e.g., in vivo, by administering a composition comprising miRNA17-92 cluster oligonucleotides, e.g., miR-19a oligonucleotides, miR-19b oligonucleotides, or both miR-19a and miR-19b oligonucleotides.... Agent: Children's Medical Center Corporation

20140219976 - Methods and compositions for treatment of retinal degeneration: Disclosed herein are methods and compositions for treating glaucoma, using descendents of marrow adherent stem cells that have been engineered to express an exogenous Notch intracellular domain.... Agent:

20140219975 - Switch costimulatory receptors: The present invention relates generally to a fusion protein that when displayed on a cell can convert a negative signal into a positive signal in the cell. The fusion protein is a chimeric protein in that the protein comprises at least two domains, wherein the first domain is a polypeptide... Agent:

20140219974 - Targeted delivery of proteins across the blood-brain barrier: Embodiments of the invention are directed to compositions comprising a peptide sequence, or a nucleic acid encoding the same, wherein the peptide sequence includes a receptor-binding region of apolipoprotein E (apoE), or a sequence variant or fragment thereof, for directing delivery of a given protein or therapeutic across the blood... Agent: Children's Hospital Medical Center

20140219966 - Fecal lactoferrin as a biomarker for determining disease severity and for treating infection in patients with clostridium difficile disease: Clostridium difficile disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of C. difficile are treated differently depending on severity of disease. Mild and moderate cases may be treated with metronidazole while moderate-to-severe and relapsing cases are often treated... Agent: Techlab, Inc.

20140219967 - Poly (3-hydroxybutyrate/3-hydroxyvalerate) of lowered crystallinity for use in animal feed: Animal feed conversion ratio can be increased and blood glucose levels can be decreased by feeding an efficacious amount of dispersible amorphous poly(3-hydroxybutyrate/3-hydroxyvalerate).... Agent: Kemin Industries, Inc.

20140219977 - Use of live bacteria for growth promotion in animals: The present invention relates to the use of F4+ non-pathogenic Escherichia coli strains to promote growth in an animal. The present invention also relates to the use of such strains to homogenize growth among a herd of animals. More specifically, the animal(s) of interest in the present invention are those... Agent: Valorisation - Recherche, Limited Partnership

20140219968 - Novel salmonella bacteriophage compositions and uses thereof: The present invention relates to novel bacteriophages and bacteriophage cocktails containing the novel bacteriophages and or parts and/or products of them, all of them belonging to the Caudovirales order. The novel bacteriophages and the bacteriophage cocktails containing the novel bacteriophages and or parts and/or products of them are Salmonella specific... Agent: Universitat Autonoma De Barcelona

20140219971 - Algal produced malarial transmission blocking vaccines: The present invention relates to the production of malaria transmission blocking vaccines in single-celled green algae, particularly algae of the genus Chlamydomonas, e.g., Chlamydomonas reinhardtii; the immunogenic Plasmodium polypeptides produced and compositions comprising them; and methods for preventing, ameliorating, reducing, delaying, treating and blocking the transmission of malaria by administration... Agent: The Regents Of The University Of California

20140219969 - Cell therapy for the treatment of neurodegeneration: Methods are described for the isolation and selection of a heterogeneous bone marrow cell population, called NCS-01, that is effective at treating neurodegeneration. For example, NCS-01 cells are shown to treat neurodegeneration caused by ischemia. In vivo studies demonstrate that selected NCS-01 cell populations treat neurodegeneration in a standard rat... Agent: Nc Medical Research Inc.

20140219973 - Composite hydrogel-clay particles: A nanocomposite hydrogel formed from free radical dissociation of an initiator and polymerisation of a water soluble monomer. The resulting hydrogel finds particular application within the medical field for both soft and hard tissue repair in human and animals. The hydrogel is particularly advantageous for spinal disc repair.... Agent:

20140219972 - Tissue engineering using progenitor cells to catalyze tissue formation by primary cells: Methods of regenerating tissue using progenitor cells in combination with primary cells from a target tissue are disclosed. In particular, progenitor cells catalyze proliferation and tissue production by primary cells allowing the use of fewer primary cells from a target tissue for effective tissue regeneration. Cell-based therapies combining progenitor cells... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20140219970 - Treatment of sarcoidosis using placental stem cells: Provided herein are compositions and methods of treating individuals having sarcoidosis or a sarcoidosis-related disease or disorder, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein. Also provided herein are kits comprising said cells or a composition thereof.... Agent: Anthrogenesis Corporation

20140219978 - Gp100-specific t cell receptors and related materials and methods of use: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services

20140219979 - Hsp60, hsp60 peptides and t cell vaccines for immunomodulation: The present invention provides novel uses for peptide p277—positions 437-460 of human heat shock protein 60 (HSP60)—in modulation of immune responses and inflammatory diseases. The invention further provides novel uses for HSP60 and p277 in the treatment or prevention of hepatic disorders. The invention discloses methods for treating, preventing or... Agent: Yeda Research And Development Co. Ltd.

20140219980 - Treatment for mitochondrial neurogastrointestinal encephalomyopathy (mngie): The invention provides a method of treating mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) in a patient, comprising administering to the patient autologous erythrocytes that contain thymidine phosphorylase and are free of animal proteins other than proteins derived from the patient. The erythrocytes generally contain a low amount of endotoxin.... Agent: St. Georges Hospital Medical School

20140219981 - Amphiphilic peptides and hydrogel matrices thereof for bone repair: The present invention relates in general to the field of tissue engineering and more specifically to amphiphilic peptides and peptide matrices thereof useful in vitro and in situ biomineralization and inducing bone repair. The present invention provides peptides, which are useful in hydrogels and other pharmaceutical compositions, and methods and... Agent: Ben-gurion University Of The Negev Research And Development Authority

20140219982 - Exogenous opioid peptide-degrading enzyme: The present invention is intended to provide a means for efficiently degrades exogenous opioid peptides. Provided is an exogenous opioid peptide-degrading enzyme preparation which contains one or more components selected from the group consisting of enzyme preparations from Penicillium citrinum, Aspergillus oryzae, and Aspergilius melleus, and exhibits a degradation activity... Agent: Amano Enzyme Inc.

20140219983 - Suppression of cancers: The present invention relates to a method for suppressing or treating cancer, in particular to a method for suppressing or treating one or more of colorectal cancer, breast cancer, prostate cancer and/or lung cancer. The therapy employs use of a non-cytotoxic protease, which is targeted to a growth hormone-secreting cell... Agent: Syntaxin Limited

20140219985 - Disease control with tick phospholipase a2: The present invention relates to reagents and methods for the modulation of viability of bacteria. A process is provided wherein a protein sequence from A. americanum saliva effective in reducing the viability of gram positive, gram negative, or acid-fast bacteria and spirochetes including B. burgdurferi is administered. The inventive protein... Agent: The United States Of America,as Represented By The Secretary,department Of Health And Human Services

20140219984 - The use of alkaline phosphatase for preserving renal function: The invention relates to the field of medicine and in particular to means and methods for preserving renal function after a treatment with a risk of reducing renal function. The present invention also relates to means and methods for shortening the duration of renal replacement therapy, increasing the creatinine clearance... Agent: Am-pharma B.v.

20140219986 - Dosing regimens for the treatment of fabry disease: The presently disclosed subject matter provides a dosing regimen and administration schedule for the use of 1-deoxygalactonojirimycin and enzyme replacement therapy for the treatment of Fabry disease. The presently disclosed subject matter further provides a dosing regimen and administration schedule for the use of migalastat hydrochloride and agalsidase for the... Agent: Amicus Therapeutics ,inc.

20140219988 - Rrecombinant human saposin b protein containing phosphorylated glucose ring and use thereof: The present invention provides a means to ensure a further increase in the therapeutic effects provided by enzyme replacement therapy against lysosomal disease. The present invention is directed to a recombinant human saposin B protein containing phosphorylated carbohydrate chains, a lysosomal enzyme activator comprising such a recombinant protein, and a... Agent: Tokyo Metropolitan Institute Of Medical Science

20140219987 - Stabilized compositions of proteins having a free thiol moiety: Compositions of proteins having free thiols, and methods of making and using such compositions, are described.... Agent: Shire Human Genetic Therapies, Inc.

20140219989 - Factor ixa inhibitors: The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.... Agent:

20140219991 - Treatment and composition for wound healing: e

20140219990 - Wound cleaning chemical composition and method for manufacturing: A wound cleaning chemical composition that includes 2 gs natural salt in 100 mls of water forming a natural salt solution, 50 mgs lactoferrin in 100 mls of water forming a lactoferrin solution, 2 gs sodium bicarbonate in 100 mls of water forming a sodium bicarbonate solution and 1 ml... Agent:

20140219992 - Metal sensitive mutants of matrix metalloproteases and uses thereof: Provided herein are methods of using modified matrix metalloprotease (MMP) enzymes that exhibit regulated activity in the presence of calcium. The methods include conditionally controlling the activity of the MMPs through the use of calcium to treat fibrotic diseases or conditions involving a component of the extracellular matrix (ECM).... Agent:

20140219993 - Plant virus infection inhibitor and a method for inhibiting plant virus infection using the same: A virus infection inhibitor containing a fermentation by-product such as an amino acid fermentation by-product and a nucleic acid fermentation by-product is sprinkled onto a plant body of a plant, such as tobacco, tomato, bell pepper, and chili pepper to control a disease induced by infection of a virus such... Agent: Ajinomoto Co., Inc.

20140219994 - Molybdate-free sterilizing and pasteurizing solutions: The present invention concerns a composition and method of using non-molybdate corrosion inhibitors in sterilizing and pasteurizing applications. The composition is a blend of one or more components including corrosion inhibitors, surfactants, hydrotropes, polymer dispersants, pH adjusting agents and water. The composition may include two or more of a) alkyl-dicarboxylic... Agent:

20140219998 - Armet as a marker for cancer: Disclosed is a method aiding in the assessment of cancer. More specifically disclosed is the use of the arginine-rich metastasized in early tumors protein (=ARMET) as a universal marker of different cancer types. ARMET aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of... Agent: Roche Diagnostics Operations, Inc.

20140219995 - Inhibitors of bacterial type iii secretion system: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Pseudomonas spp., Yersinia spp., enteropathogenic and enteroinvasive... Agent: Microbiotix, Inc.

20140219996 - Ruthenium carbon monoxide releasing molecules and uses thereof: The present invention provides novel ruthenium compounds of Formula (I): or salts, isomers, hydrates, or solvates thereof, or combinations thereof; wherein E, R1, R2, R3, R4, R5, X1, and X2 are as defined herein, and pharmaceutical compositions thereof. Also provided are methods of use and treatment. Such compounds have been... Agent: Alfama- Investigacao E Desenvolvimento De Produtos Farmac&#xea Uticos, Lda.

20140219997 - Templated islet cells and small islet cell clusters for diabetes treatment: A population of small reaggregated islets or clusters engineered from individual islet cells and having improved characteristics as compared to native isolated islets.... Agent: The University Of Kansas

20140220002 - Combination therapies employing gitr binding molecules: The present invention provides combination therapies that employ a GITR binding molecule in combination with one or more additional agents.... Agent: Gitr, Inc.

20140220009 - Compositions and methods for treating cocaine-related disorders: A method of treating a cocaine-related disorder in an individual is provided, the method including administering to the individual a therapeutic amount of an antibody comprising a human immunoglobulin gamma heavy chain and a murine lambda light chain. In a specific embodiment, the antibody is a monoclonal antibody comprising a... Agent: University Of Cincinnati

20140220004 - Compositions and methods for treating pain: Provided herein are compositions containing an antibody or antigen-binding antibody fragment that specifically binds to metallothionein 2 (MT2) protein, and compositions containing an agent that binds to or neutralizes a function of MT2 protein and/or an oligonucleotide that decreases the expression of MT2 mRNA in a mammalian cell, and optionally,... Agent: Children's Medical Center Corporation

20140220008 - Humanized anti-cd4 antibody with immunosuppressive properties: A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.... Agent: Biotest Ag

20140220006 - Lung cancer biomarkers: The present invention relates to methods of diagnosing lung cancer in a patient, as well as methods of monitoring the progression of lung cancer and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with... Agent: Meso Scale Technologies, LLC

20140220007 - Lupus biomarkers: The present invention relates to methods of diagnosing lupus in a patient, as well as methods of monitoring the progression of lupus and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic... Agent: Meso Scale Technologies, LLC

20140220001 - Methods and monitoring of treatment with a dll4 antagonist: Methods for treating diseases such as cancer comprising administering a DLL4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.... Agent: Oncomed Pharmaceuticals, Inc.

20140220000 - Mhc engagement and clip modulation for the treatment of disease: The invention relates to methods for treating disorders by targeting CLIP molecules and MHC. The methods are useful for treating, inhibiting the development of, or otherwise dealing with diseases such as HIV, blood vessel proliferative disorder, cancer and fibrosis.... Agent: The Texas A&m University System

20140220005 - N-cadherin: target for cancer diagnosis and therapy: The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers that express N-cadherin, including prostrate and bladder cancers.... Agent: The Regents Of The University Of California

20140220003 - Therapeutic method for mesothelioma: The present invention relates to a therapeutic method and a diagnostic method using an antibody that binds to a ganglioside GM2 antigen, and a therapeutic agent and a diagnostic agent comprising as an active ingredient an antibody that binds to a ganglioside GM2 antigen. According to the present invention, the... Agent: National University Corporation Kanazawa University

20140219999 - Treatment of colon cancer using complement inhibitors: Methods for treating, preventing or delaying onset of polyp formation and subsequent colon cancer are disclosed. The methods involve administration of a complement inhibitor to inhibit C5a receptor signaling in the tumorigenic or pre-tumorigenic tissue.... Agent: The Trustees Of The University Of Pennsylvania

20140220010 - Variants of humanized immunomodulatory monoclonal antibodies: The present invention relates to humanized monoclonal antibodies, pharmaceutical compositions that include the same, and use thereof for the treatment of a variety of indications, particularly cancer and immunodeficiency disorders. In particular, the present invention provides modified antibodies or fragments thereof having specific amino acid modifications compared to the humanized... Agent: Curetech Ltd.

20140220016 - Antibody- endostatin fusion protein and its variants: Methods of inhibiting the growth of tumors comprising administering chimeric fusion molecules comprising endostatin mutants and all or a portion of anti-Her2 or anti-EGFR antibodies.... Agent: University Of Miami

20140220015 - Combinations of modalities for the treatment of diabetes: A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a T-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a Type 1 diabetes autoantigen. The method includes, for... Agent: Orban Biotech LLC

20140220014 - Levels of bcma protein expression on b cells and use in diagnostic methods: The present invention provides a method of measuring the levels of BCMA in a biological sample, specifically upon the B cell surface. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE, and for methods for treating an... Agent: Zymogenetics, Inc.

20140220013 - Method for the diagnosis and prognosis of malignant diseases: Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin.... Agent: University Of Louisville Research Foundation, Inc.

20140220012 - Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders: The present invention relates to a fusion proteins comprising regulatory T cell protein, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation (PD-L3) and an immunoglobulin protein (Ig), preferably also containing a flexible linker intervening the VISTA and Ig Fc polypeptide. The invention also provides the use of VISTA polypeptides, multimeric... Agent:

20140220011 - Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, ClORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung... Agent: Compugen Ltd.

20140220017 - Serum half-life extension using igbd: The present invention relates to complexes comprising (i) an immunoglobulin (Ig) binding moiety and (ii) a pharmaceutically active moiety, wherein the Ig binding moiety specifically binds to the constant domain 1 of the heavy chain (CH1) of an Ig molecule and their use for therapy and prophylaxis.... Agent:

20140220018 - Biomarkers for epithelial cancer diagnosis and treatment: Disclosed herein are methods for diagnosing the state of an epithelial tumor or tissue in a subject. Also disclosed are methods of diagnosing tumor initiation in an epithelial tissue of a subject. Also disclosed are methods of determining prognosis of a subject with an epithelial tumor. These methods include, in... Agent:

20140220019 - Dual variable domain immunoglobulins and uses thereof: Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.... Agent: Abbvie, Inc.

20140220020 - Il-1 binding proteins: Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions.... Agent: Abbvie, Inc.

20140220021 - Therapeutic agent for autoimmune diseases comprising pd-1 agonist: Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients. The prophylactic, symptom progress-suppressive, and/or therapeutic agent includes a PD-1 agonist as an active ingredient and is administered (a) 1 to 10... Agent: Ono Pharmaceutical Co., Ltd.

20140220027 - 1d05 pcsk9 antagonists: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host... Agent: Merck Sharp & Dohme Corp.

20140220028 - Antibodies directed against signal peptides, methods and uses thereof: Provided are methods employing antibodies directed against the signal peptide (SP) domain of various disease-associated polypeptides. These anti-SP antibodies detect cell surface expression of these SP domains and are used in methods of diagnosis and/or therapy. Provided is a method for determining the suitability for treatment of a subject suffering... Agent: Vaxil Biotherapeutics Ltd.

20140220024 - Chymase compositions, antibodies, diagnostics, and therapeutic methods related thereto: The disclosure relates to chymase, antibodies to chymase, and diagnostic and therapeutic methods relates thereto. It has been discovered that above certain circulating levels of chymase, a patient has a high likelihood of AVF nonmaturation. Compositions and methods of detecting and measuring chymase levels are disclosure herein. In certain embodiments,... Agent: Emory University

20140220023 - Method of treating osteoarthritis with an antibody to ngf: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.... Agent: Regeneron Pharmaceuticals, Inc.

20140220025 - Novel stip1 polypeptides and uses thereof: The present invention is directed toward pharmaceutical compositions comprising an isolated polypeptide and a pharmaceutically acceptable carrier. The present invention also discloses an antibody or an antigen-binding portion thereof that bind to the isolated polypeptide. Methods of inhibiting cancer cells growth are also disclosed, comprising administering the isolated polypeptide or... Agent: Chang Gung Memorial Hospital, Linkou Branch

20140220022 - Pthrp, its isoforms and antagonist thereto in the diagnosis and treatment of disease: The present invention is directed to the diagnosis and treatment of diseases, preferably the inhibition of tumor growth and its progression to metastatic sites, through the inhibition of the production of PTHrP, its isoforms or PTHrP signalling. The present invention is also directed to methods of inhibiting the PTHrP1-173 isoform... Agent: Biochrom Pharma Inc.

20140220026 - Therapeutic use of specific ligand in msrv associated diseases: A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as... Agent: Geneuro Sa

20140220029 - Combined use of a modulator of cd3 and a glp-1 compound: Methods and uses for the prevention and intervention of Type 1 diabetes comprising administration of a modulator of CD3 and a GLP-1 compound.... Agent: Novo Nordisk A/s

20140220033 - Administration of an anti-activin-a compound to a subject: The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A... Agent: Amgen Inc.

20140220031 - Anti-cd154 antibodies: The present invention provides peptides, and fragments thereof, and antibodies, or fragments thereof comprising the same, wherein the peptide comprises at least one amino acid substitution compared to wild type 5c8 antibody. The present invention also provides compositions and methods of treating CD154-related diseases or disorders in a subject.... Agent: Biogen Idec Ma Inc.

20140220032 - Ddr2 mutations as targetable features of melanoma or basal cell carcinoma: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue... Agent: Quest Diagnostics Investments Incorporated

20140220035 - Method for detecting novel fgfr4 mutant: s

20140220034 - Serpinf2-binding molecules and method of use thereof: Compositions and methods of using SerpinF2-binding molecules for preventing and/or reducing organ damage, functional disability or mortality in a patient at risk due to the activity of SerpinF2 and/or plasminogen activators on tissue injury. Also provided are compositions and methods of using SerpinF2-binding molecules for inhibiting hemorrhage, edema, and apoptosis.... Agent: Translational Sciences Inc.

20140220030 - Use of cgrp antagonist compounds for treatment of psoriasis: The invention provides methods and compositions for treating, preventing and/or remedying psoriasis, based on compounds that have a calcitonin-related gene peptide (CGRP) antagonistic effect. Methods are also disclosed for identifying compounds with CGRP antagonist activity which thereby are suitable candidate compounds for treating psoriasis.... Agent:

20140220040 - Antibodies to lrp6: Anti-LRP6 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. These anti-LRP6 antibodies can be used to enhance Wnt activity and/or antagonize Dkk1 activity. Also described are methods of therapy using such antibodies and antigen-binding regions to bind modulate Wnt/LRP6 signaling... Agent: Arca Biopharma, Inc.

20140220039 - Apoiii and the treatment and diagnosis of diabetes: The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes comprising contacting pancreatic β cells with an amount of apolipoprotein CIII (“apoCIII”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit... Agent: Biocrine Ab

20140220041 - Compounds for use in the treatment of alzheimer's disease: The invention relates to a method of modulating concentration of Alzheimer's Disease (AD) relevant proteins amyloid precursor protein (APP), beta (β) and gamma (γ) secretases and amyloid beta peptide (Aβ), and also relates to a method of reducing Aβ shedding. Furthermore, this invention extends to a compound for use in... Agent: University Of The Witwatersrand, Johannesburg

20140220038 - Lrp1 as key receptor for the transfer of sterified cholesterol from very-low-density lipoproteins (vldl) to ischaemic cardiac muscle: The invention relates to novel molecules that can modulate one of the mechanisms leading to the massive deposition of cholesterol in the cardiomyocytes and/or in the smooth muscle cells of the vascular wall, during acute myocardial infarction or other clinical situations involving ischaemia. The invention also shows that the blockage... Agent:

20140220036 - Methods for treating neurodegenerative diseases and for identifying agents useful for treating neurodegenerative diseases: The present invention provides methods of inhibiting a tau protein such as h-tau42 or a biologically active fragment, derivative or analog thereof, methods of treating a disease caused by a tau protein such as h-tau42, and methods to identify agents that may inhibit a tau protein such as h-tau42. The... Agent:

20140220037 - Methods for treating reperfusion injuries: The present invention relates to treating a tissue in a mammal from the effects of reperfusion using flagellin... Agent: Cleveland Biolabs, Inc.

20140220042 - Anti-c (epsilon)mx antibodies capable of binding to human mige on b lymphocytes: The invention pertains to the generation and utility of antibodies that can bind effectively to CεmX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The CεmX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound... Agent: Academia Sinica

20140220043 - Gene signature for predicting prognosis of patients with solid tumors: Disclosed herein is a driver gene signature for predicting survival in patients with solid tumors, such as hepatocellular carcinoma (HCC) and breast cancer. The gene signature includes ten tumor-associated genes, SH2D4A, CCDC25, ELP3, DLC1, PROSC, SORBS3, HNRPD, PAQR3, PHF17 and DCK. A decrease in DNA copy number or mRNA expression... Agent: The United States Of America, As Represented By The Secretary, Department Of Health And Human

20140220045 - Compositions of a peptide targeting system for treating cancer: This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques.... Agent: Nanooncology, Inc.

20140220044 - Method for the production of hydrolyzed allergens: i

20140220047 - Monomethylvaline compounds capable of conjugation to ligands: Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.... Agent: Seattle Genetics, Inc.

20140220046 - Sialic acid derivatives for protein derivatisation and conjugation: Derivatives are synthesised of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted... Agent: Lipoxen Technologies Limited

20140220048 - Apoptotic cell-mediated transfection of mammalian cells with interfering rna: Mammalian host cells for use in a cell-mediated tranfection process, which contain an RNAi molecule and an expression vector for a pro-apoptotic protein. The method includes inducing apoptotic cell (AC) death in mammalian cells that contain an RNAi molecule capable of downregulating a chosen target gene. Living cells expressing the... Agent: Loma Linda University

20140220052 - Compositions and methods for wound healing, and for recruitment and activation of macrophages in injured tissues and in implanted biomaterials used for tissue engineering: The present invention is related to the field of wound healing or tissue regeneration due to disease (i.e., for example, cardiovascular diseases, osetoarthritic diseases, or diabetes) and to healing of internal injuries. In particular, the present invention provides compositions and methods comprising molecules and nanoparticles with linked α-gal epitopes for... Agent: University Of Massachusetts

20140220051 - Methods of modulating hvem, btla and cd160 cis complex response or signaling activity with soluble light polypeptide sequences: The invention provides HVEM cis complexes which include, for example, HVEM/BTLA, HVEM/CD160 and HVEM/gD cis complexes. The invention provides ligands and agents that bind to HVEM cis complexes, such as antibodies. The invention further provides methods of use of the HVEM cis complexes, and the ligands and agents (e.g., LIGHT... Agent:

20140220049 - Microrna inhibition for the treatment of inflammation and myeloproliferative disorders: The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing an treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of... Agent: California Institute Of Technology

20140220053 - Microvesicles isolated from mesenchymal stem cells for use as immunosuppressive agents: The present invention concerns microvesicles isolated from mesenchymal stem cells as immunosuppressive agents for treatment of inflammatory and immune pathologies.... Agent:

20140220050 - Novel immunomodulator and anti-inflammatory compounds: The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.... Agent: Rhizen Pharmaceuticals Sa

20140220056 - Vaccine composition for transdermal administration: Disclosed is a vaccine composition for transdermal administration to induce cellular immunity, comprising an antigen, wherein Th1 cell ratio in a model animal for immunological evaluation that received the composition is 10% or more.... Agent:

20140220058 - Vaccine composition for transdermal or mucosal administration: The invention provides a vaccine composition for transdermal or transmucosal administration for inducing cellular immunity, comprising (i) an antigen; and (ii) a pharmacologically acceptable acid or a pharmacologically acceptable salt thereof as a first cellular immunity induction promoter.... Agent:

20140220054 - Wt1 hla class ii-binding peptides and compositions and methods comprising same: This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.... Agent:

20140220059 - Wt1 peptide cancer vaccine composition for mucosal administration: The present invention provides a cancer vaccine composition for mucosal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject.... Agent:

20140220055 - Wt1 peptide cancer vaccine composition for transdermal administration: The present invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a cellular immunity induction promoter. The composition efficiently induces cellular immunity against a cancer in a subject.... Agent:

20140220057 - Wt1 peptide cancer vaccine composition for transdermal administration: The present invention provides a cancer vaccine composition for transdermal administration for cellular immunity induction, comprising (i) a WT1 peptide and/or a modified WT1 peptide; and (ii) a pharmacologically acceptable acid as a first cellular immunity induction promoter, or a pharmacologically acceptable salt thereof.... Agent:

20140220062 - Conditional replicating cytomegalovirus as a vaccine for cmv: The present invention relates to methods of inducing an immune response to cytomegalovirus (CMV) using a genetically modified CMV that is conditionally replication defective. The methods of the invention can be used to treat and/or prevent primary CMV infection, infection due to reactivation of a latent CMV and a super-infection... Agent:

20140220060 - Hiv-1 south african subtype c env proteins: The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations... Agent: Novartis Vaccines & Diagnostics, Inc.

20140220061 - Yeast expression of flavivirus virus-like particles and use thereof: Described herein is a method for the production of flavivirus virus-like particles (VLPs) in a yeast system. In some cases, flavivirus structural proteins are expressed in a Pichia pastoris strain and isolated using pressurized mechanical lysis. The disclosed VLPs can be used as immunogenic compositions for the prevention or treatment... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education

20140220063 - Vaccine composition: The invention provides a vaccine composition containing an antigen for inducing cellular immunity, comprising at least one first cellular immunity induction promoter.... Agent:

20140220066 - Group a streptococcus multivalent vaccine: Immunogenic compositions are provided herein that are useful for inducing an immune response specific against group A streptococcus (GAS). Immunogenic compositions provided herein are multivalent and comprise a plurality of immunogenic peptides or fusion polypeptides comprising the immunogenic peptides that induce an immune response against GAS. The immunogenic compositions provided... Agent: University Of Tennessee Research Foundation

20140220064 - Immunizing composition: The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both of S. equi subsp. equi and subsp. zooepidemicus and use thereof for immunization of non-human mammals against... Agent:

20140220065 - Therapeutic application of s. pyogenes c-terminal peptide: A method for treating rheumatic heart disease comprising administering an immunogenic composition against group A beta hemolytic streptococcus... Agent:

20140220067 - Live attenuated chimeric porcine circovirus vaccine: The present invention provides a novel chimeric porcine circovirus infectious DNA clone and live attenuated chimeric virus with the PCV2, preferably of subtype PCV2b, capsid gene integrated into a non-pathogenic PCV1 virus genome. In a particular embodiment, the PCV2 capids gene is of subtype PCV2b, the predominant subtype circulating in... Agent: Virginia Tech Intellectual Properties, Inc.

20140220069 - Active ingredient derived from torulaspora delbrueckii and cosmetic use for improving and/or repairing the barrier function of the skin: An active ingredient derived from Torulaspora delbrueckii and the use thereof for improving and/or restoring the barrier function of the skin. Also, cosmetic compositions containing this active ingredient and a cosmetic care process for improving and/or restoring the barrier function of the skin.... Agent: Societe Industrielle Limousine D'application Biologique

20140220068 - Novel xylogone ganodermophthora strain with antifungal activity, and composition including same for preventing plant diseases: A novel ascomycetous Xylogone ganodermophthora strain has antifungal activity. A composition includes the strain as an active ingredient for preventing plant diseases. The strain suppresses the growth of pathogenic fungi, including Phytophthora capsici, in plants. Therefore, the composition containing the strain, or a culture or extract thereof, as an active... Agent: The Director Of Chungcheongbuk-do Agricultutal Research And Extension Services

20140220071 - Biologically active food additive for normalizing the function of the thyroid gland: An active biologically active dietary additive for the normalization of the thyroid gland function contains roots, rhizomes or the herb of white cinquefoil, or their mixture, Echinacea purpurea, and Laminaria, the ratio in mass percent being: white cinquefoil—10-75, Echinacea purpurea—10-50, Laminaria—10-80.... Agent: Jsc Patent Attorney

20140220070 - Use of plant cell membrane treatment of obesity: The present invention relates to the use of a composition comprising at least one cell membrane fraction or parts thereof, for the reduction of lipolytic activity and/or to retard fat digestion, suppress appetite, body weight and/or lower blood lipids. The invention also relates to the use of said hydrophobic peptide... Agent: Thylabisco Ab

20140220072 - Shigella-derived vector and methods of using the same: Recombinant vectors comprising the cell entry region of the Shigella ox EIEC invasion plasmid are provided, as well as, Shigella or EIEC strains comprising the recombinant vectors. The vectors provide an improved platform for developing attenuated vaccine strains of Shigella or EiEC and for delivering other foreign proteins of interest.... Agent: The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc

20140220073 - Immunization compositions and methods: The present invention provides methods and compositions to induce neutralizing antibodies in mammals to serotypes of dengue virus, measles virus, mumps virus, rubella and/or VZV virus.... Agent: Sanofi Pasteur Sa

20140220074 - Toll-like receptor 4 (tlr-4) agonist peptides for modulating tlr-4 mediated immune response: Peptides including an amino acid sequence of a fragment of mammalian Toll-like receptor-4 (TLR-4), analogs and derivatives thereof, and pharmaceutical compositions including these peptides. Methods for modulating a TLR-4 mediated immune response, particularly stimulating TLR-4 mediated immune response, thereby treating infectious diseases and cancer.... Agent: Yeda Research And Development Co. Ltd.

20140220075 - Multi plasmid system for the production of influenza virus: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided.... Agent: Medimmune, LLC

20140220076 - Recombinant mistletoe lectin and use thereof as an adjuvant: The invention relates to vaccines that comprise antigens and an adjuvant, and to the use of the adjuvant, wherein the adjuvant is selected from a recombinant mistletoe lectin.... Agent: Cytavis Biopharma Gmbh

20140220077 - New modified live flavobacterium strains, stabilized vaccines comprising same, and methods of making and use thereof: The present invention provides attenuated F. columnare strains that elicit an immune response in an animal, particularly a fish, against virulent F. columnare compositions comprising said strains, methods of vaccination against F. columnare, and kits for use with such methods and compositions. The invention further relates to a stabilization buffer,... Agent: Auburn University

20140220078 - Method for preparing glucans based on aspergillus niger: e

20140220079 - Vaccine composition for mucosal administration: The present invention provides a cancer vaccine composition for mucosal administration comprising (i) a HER2/neu E75 peptide and/or a modified HER2/neu E75 peptide; and (ii) a first cellular immunity induction promoter.... Agent:

20140220080 - Iga secretion promoter: Provided is a novel IgA secretion promoter useful as a mucosal immunity stimulation agent and a method of promoting IgA secretion in a body of animal to stimulate mucosal immunity. A significant action of promoting IgA secretion was observed in oral administration of indigestible dextrin.... Agent:

20140220081 - Use of a galactose-derived c-glycoside compound as an agent for activating and regulating cutaneous immunity: The present invention relates to novel galactose derivatives of general formula (I) and their use as agents for stimulating the immune system of the skin and/or as immunoregulators, and for preparing a composition containing a cosmetically or pharmaceutically acceptable medium, intended in particular to prevent and/or limit the appearance of... Agent: L'oreal

20140220082 - Adhesive complex coacervates and methods of making and using thereof: Described herein is the synthesis of adhesive complex coacervates and their use thereof. The adhesive complex coacervates are produced by reacting (a) at least one poly anion comprising a plurality of activated ester groups, and (b) at least one polycation comprising a plurality of nucleophilic groups, wherein the nucleophilic groups... Agent: University Of Utah Research Foundation

20140220086 - Antimicrobial compositions and methods of use thereof: Antimicrobial compositions including a cell penetrating peptide (CPP) having the amino acid sequence Tyr-Ala-Arg-Val-Arg-Arg-Arg-Gly-Pro-Arg-Gly-Tyr-Ala-Arg-Val-Arg-Arg-Arg-Gly-Pro-Arg-Arg (SEQ ID NO:1) or variant thereof are disclosed. The CPP, which itself has antimicrobial properties, can be advantageously combined with or conjugated to a cargo to increase the delivery, efficacy, or combinations thereof, of the cargo... Agent:

20140220083 - Cationic oil-in-water emulsions: This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are useful for delivering negatively charged... Agent:

20140220085 - Method for tissue engineering: In an embodiment of the disclosure, a biomedical material is provided. The biomedical material includes a biocompatible material having a surface and a carrier distributed over the surface of the biocompatible material, wherein both of the biocompatible material and the carrier have no charges, one of them has charges or... Agent: Industrial Technology Research Institute

20140220084 - Use of plant cell membrane treatment of obesity: The present invention relates to the use of a composition comprising at least one cell membrane fraction or parts thereof, for the reduction of lipolytic activity and/or to retard fat digestion, suppress appetite, body weight and/or lower blood lipids. The invention also relates to the use of said hydrophobic peptide... Agent: Thylabisco Ab

20140220089 - Composition: A solid cosmetic composition includes a vegetable butter. The solid composition has dispersed therein gas bubbles, and the gas bubbles form at least 20% of the volume of the solid cosmetic composition.... Agent: Cosmetic Warriors Ltd.

20140220090 - Cosmetic composition intended for making up the skin, cosmetic product and cosmetic use of babassu polysaccharides: s

20140220088 - Methods for the production of a cosmetic composition from hatching fluid and uses thereof for improving the cosmetic appearance of skin: The present invention relates to cosmetic compositions obtained or obtainable from Salmonidae hatching fluid, methods of producing said compositions and their use in various cosmetic applications to the skin, particularly for reducing or preventing the cosmetic appearance or prevalence of wrinkles, fine lines, hyperpigmentation, laxity, dry skin, scaling and/or transepidermal... Agent: Aqua Bio Technology Asa

20140220087 - Personal care compositions that include enrobed sugar: e

20140220091 - Embedding nanoparticles in thermoplastic polymers: The present invention relates to a polymeric material having one or more nanoparticles embedded within the surface layer of a single side of the material. In some embodiments, the nanoparticles are microbiocidal nanoparticles which impart antimicrobial characteristics to the polymeric material within which they sprayed and pushed by are embedded.... Agent: Wroclaw Medical University

20140220092 - Method to remediate a mollusk infestation: A device for treating pests and method for using the same. The device comprises an effective amount of endod. The device can be placed in a body of water wherein the endod treats the pests. Additionally the device can be placed in a pipe whereby a combination of the endod... Agent:

20140220093 - Cationic polymers for antimicrobial applications and delivery of bioactive materials: wherein w′ is a positive number greater than or equal to 3, I′ is a dendritic polyester core covalently linked to w′ independent peripheral linear cationic polymer chains P′. Each of the chains P′ comprises a cationic repeat unit comprising i) a backbone functional group selected from the group consisting... Agent: International Business Machines Corporation

20140220094 - Methods and compositions for a laparoscopic surgery: Glycerophosphate salts have been found to drastically improve a laparoscopic surgery by reducing the inflammatory response inflicted by the surgery and enhancing wound healing. Methods and devices for improving the laparoscopic surgery using a composition comprising an effective amount of a glycerophosphate salt are described.... Agent: Prelief Inc.

20140220096 - Cartilage material: Cartilage materials such as cartilage fluff and a cartilage composition comprising a particulate material are disclosed. These are suitable for stimulating chondrogenesis and/or producing cartilage regeneration. Also disclosed are processes for their preparation. Methods for regenerating articular cartilage are also disclosed, which involve, for example, placing the cartilage fluff or... Agent: Vivex Biomedical Inc.

20140220097 - Method of implanting a sterile, active agent-coated material and composition made according to same: The present invention relates to a method of implanting a sterile, active agent-coated material comprising contacting a sterile implant with a sterile active agent or active agent solution to form a sterile, active agent-coated implant and, at most a relatively short time after forming the active agent-loaded sterile implant, implanting... Agent: Depuy Synthes Products, LLC

20140220095 - Methods for localized modification of tissue products: Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating select portions of a tissue matrix with a cross-linking agent and/or a proteolytic enzyme to produce a tissue matrix with variable mechanical and/or biological properties.... Agent: Lifecell Corporation

20140220098 - Drug eluting mesh to prevent infection of indwelling transdermal devices: In some embodiments, a device (102) may include a mesh having at least one bioresorbable polymer coating. The coating may comprise at least one active agent which is eluted over time. The device (102) may at least partially cover at least a portion of an implanted transdermal medical device (100).... Agent: Tyrx, Inc.

20140220099 - Biodegradable polyesteramide copolymers for drug delivery: The present invention relates to a poly (ester amide) (PEA) having a chemical formula described by structural formula (IV), wherein m+p varies from 0.9-0.1 and q varies from 0.1 to 0.9 m+p+q=1 whereby m or p could be 0 n is about 5 to about 300; (pref. 50-200) R1 is... Agent: DsmIPAssets B.v.

20140220102 - Ectocornea-like sheet and method of constructing the same: It is intended to provide a transplantation material applicable to ocular surface diseases with a need for ectocornea transplantation (i.e., an ectocornea-like sheet). Oral mucosal epithelial cells are inoculated onto an amnion and then cultured in the coexistence of supporter cells. When a layered structure of the oral mucosal epithelial... Agent:

20140220101 - Substantially dry nicotinamide pads for treatment of skin inflammation: A substantially dry nonwoven pad is provided containing a formulation comprising nicotinamide in an amount between about 1% to about 10% w/w based on the total weight of the formulation and at least one water-soluble gritty polymer in an amount between about 10% to about 75% w/w based on the... Agent:

20140220100 - Vaccine composition for transdermal administration: The invention provides a cancer vaccine composition for transdermal administration for inducing cellular immunity comprising (i) HER2/neu E75 peptide and/or a modified HER2/neu E75 peptide; and (ii) a first cellular immunity induction promoter.... Agent:

20140220103 - Hemostatic dressing for arterial bleeding: A wound treatment system having a formulation to retard bleeding. In particular, the wound treatment system includes medical device, e.g. bandage, which can be adapted for internal or external use. The wound treatment system includes a fabric substrate having a formulation, wherein the formulation includes chitosan, kaolin, fibrinogen, and thrombin.... Agent: The Trustees Of Columbia University In The City Of New York

20140220104 - Patch containing rivastigmine: The present invention relates to a rivastigmine-containing patch having improved storage stability and proper release property.... Agent: Sk Chemicals Co., Ltd.

20140220105 - Tape preparation of wt1 peptide cancer vaccine for transdermal administration: e

20140220108 - Cochleate compositions and methods of making and using same: The present invention provides, in part, cochleate compositions and methods for making and using same.... Agent: Coordinated Program Development, LLC

20140220117 - Cytotoxic t lymphocyte inducing immunogens for prevention treatment and diagnosis of cancer: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as pancreatic carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against pancreatic and other cancers.... Agent: Immunotope, Inc.

20140220106 - Lymphatic zip codes in tumors and pre-malignant lesions: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.... Agent: Sanford-burnham Medical Research Institute

20140220113 - Method and medicament for inhibiting the expression of a given gene: The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA.... Agent: Alnylam Pharmaceuticals, Inc.

20140220116 - Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface... Agent: Engeneic Gene Therapy Pty Limited

20140220114 - Methods for treating niemann-pick type c disease: The present invention includes methods for treating Niemann-Pick Type C disease through administration of inhibitors of acyl-coenzyme A:cholesterol acyltransferase 1 (ACAT1). ACAT inhibitors are used to treat symptoms of Niemann-Pick Type C disease and prolong survival of patients with the disease, either alone or in combination with other treatments.... Agent: Trustees Of Dartmouth College

20140220115 - Nanoparticle arsenic-platinum compositions: The present invention relates to nanoparticle encapsulated arsenic and platinum compositions and methods of use thereof. In particular, the present invention provides co-encapsulation of active forms of arsenic and platinum drugs into liposomes, and methods of using such compositions for the diagnosis and treatment of cancer.... Agent: Northwestern University

20140220109 - Novel cochleate formulations: A process for producing a small-sized, lipid-based cochleates. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca2+ or Zn2+, forms a... Agent: Rutgers, The State University Of New Jersey

20140220110 - Remote loading of sparingly water-soluble drugs into liposomes: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a... Agent:

20140220111 - Remote loading of sparingly water-soluble drugs into liposomes: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a... Agent:

20140220112 - Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes: Sparingly water-soluble agents can be formulated as cyclodextrin complexes, however, these water-soluble drug-cyclodextrin complexes dissociate when the complex is administered into patients. The dilution of the complex in the patient leads to the drug being released from the complex, so the drug is not effectively targeted. In contrast, drugs encapsulated... Agent:

20140220107 - Truncated hiv envelope proteins (env), methods and compositions related thereto: The instant application provides methods and related compositions pertaining to novel HIV envelope proteins. In some embodiments, the invention relates to methods and compositions for the preparation, production, and administration of isolated novel HIV envelope nucleic acid and protein sequences suitable, for example, as vaccines against HIV.... Agent: The Government Of The Usa, As Represented By The Secretary

20140220118 - Solid formulations of ospemifene: e

20140220119 - Capsules containing high doses of levodopa for pulmonary use: The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein... Agent: Civitas Therapeutics, Inc.

20140220120 - Crystal entecavir, crystal entecavir formulation and methods for the preparation thereof: The present invention relates to a pharmaceutical composition for treating hepatitis B virus infection comprising crystalline entecavir as the pharmaceutically active ingredient and one or more pharmaceutically acceptable excipients. The tablet and capsule of the pharmaceutical composition have improved stability compared to that of amorphous entecavir under the conditions of... Agent: Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory

20140220122 - Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid: The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not... Agent: Bhi Limited Partnership

20140220121 - Novel formulation of diclofenac: The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way... Agent: Iceutica Pty Ltd.

20140220126 - Abuse-deterrent pharmaceutical compositions for controlled release: The present disclosure relates to pharmaceutical compositions that are abuse resistant and may also provide controlled release. The present disclosure also relates to the use of pharmaceutical compositions in the treatment of pain.... Agent: Egalet Ltd.

20140220124 - Combination tablet with chewable outer layer: A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is... Agent: Vitalis LLC

20140220123 - Pharmaceutical compositions comprising niacin and a process for their preparation: A process for the manufacture of compositions containing niacin, the process including a first compaction step of niacin or a pharmaceutically acceptable salt thereof, then a second compaction step of a dry blend comprising niacin and microcrystalline cellulose and a further compression step into tablets. Stable tablet compositions including niacin... Agent: Pharma Pass Ii LLC

20140220127 - Reduction of opioid blood fluctuations: The present invention relates to the use of a sustained release matrix containing at least one opioid for producing a solid oral formulation in table form suitable for reducing blood concentration fluctuations of said opioid.... Agent: Ethypharm

20140220125 - Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors: The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.... Agent: Novartis Ag

20140220128 - Solid dosage form: A solid dosage form comprises coated particles of bisphosphonate or a pharmaceutically acceptable analogue or derivative thereof.... Agent: Arrow International Limited

20140220129 - Compositions comprising s-adenosylmethionine and a gallic acid ester: Provided herein are compositions and formulations comprising S-adenosyl-L-methionine (“SAM-e” or “SAMe”) and one or more gallic acid esters. Also provided herein are methods for improving the delivery of SAMe. Compositions and formulations provided herein increase SAMe plasma concentrations and area under the curve (AUC) values. Also provided herein are methods... Agent: Methylation Sciences International Srl

20140220130 - Device for promotion of hemostasis and/or wound healing: The present invention relates to a matrix material comprising a pharmaceutical composition such as a matrix material with a pharmaceutical composition printed on the surface. In one embodiment the pharmaceutical composition comprises thrombin. The invention further describes a method for making the matrix material with a pharmaceutical composition printed on... Agent: Ferrosan Medical Devices A/s

20140220142 - Composition for bone regeneration: The present invention provides a composition for bone regeneration comprising: particulate demineralized bone matrix; fibrous demineralized bone matrix; and a hydrate. In addition, it is preferable that the present invention comprises a demineralized solution-derived isolated product obtained by neutralizing a demineralized solution, separated from a demineralization process, and separating the... Agent: Cg Bio Co., Ltd.

20140220140 - Compositions of efavirenz: The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug efavirenz. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester,... Agent: The University Of Liverpool

20140220141 - Compositions of lopinavir and ritonavir: The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drugs lopinavir and ritonavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty... Agent: The University Of Liverpool

20140220138 - Enhanced nitric oxide delivery and uses thereof: Methods and compositions are disclosed that enhance delivery of nitric oxide (NO) by combining nitric oxide releasing nanoparticles (NO-np) with exogenous glutathione (GSH), as well as therapeutic uses of the methods and compositions.... Agent: Albert Einstein College Of Medicine Of Yeshiva University

20140220137 - High activity antiparasitic composition against rhynchophorus ferrugineus: Synergistic composition able to rapidly and efficiently terminate Rhynchophorus ferrugineus infestation, in palms or other species suffering from this parasite. The composition comprises one or more among permethrin, cypermethrin, lambda-cyhalothrin; one or more among chlorpyrifos methyl, and chlorpyrifos ethyl; furthermore, benzisothiazolin-3-one, piperonyl butoxide, imidacloprid. The parasite dies shortly after contact... Agent: Romano Natur Gmbh

20140220134 - Method for treating diabetes with extended release formulation of glp-1 receptor agonists: The disclosure provides methods for treating diabetes, treating overweight, treating obesity, reducing body weight, treating cardiovascular diseases, treating fatty liver diseases, treating gastrointestinal diseases, and treating neurodegenerative diseases through the once monthly administration of pharmaceutical formulations containing a non-aqueous carrier and GLP-1 receptor agonists that provides therapeutically effective plasma concentration... Agent: Amylin Pharmaceuticals LLC

20140220133 - Nanotechnology based medicine for biodefense: A composition and methods to bind and remove toxic agents from a subject exposed to the toxic agents are described herein. The composition comprises a stealth agent and scavenging agent bound to a nanoparticle platform. The stealth agent prevents the nanomedicine from detection and elimination by the immune system allowing... Agent:

20140220135 - Permeation enhanced active-carrying nanoparticles: Nanoparticles having a core and a corona of ligands covalently linked to the core, wherein an active agent and a permeation enhancer are bound to or associated with the nanoparticles.... Agent:

20140220131 - Personal care compositions containing volumizing, fixative, and conditioning particles for fine hair: The present invention is directed to a personal care composition comprising: a personal care composition comprising a particle complex consisting of a hydrolyzed corn starch, a starch/cellulose polymer, a hydrogenated phospholipid, and gum arabic; and an aqueous carrier. The personal care composition is suitable for delivery as a sprayable composition... Agent:

20140220132 - Pharmaceutical formulation comprising compounds of the jasmonate family: The current invention pertains to pharmaceutical formulation including at least one jasmonate compound of the jasmonate family of compounds combined with a carrier, such as inclusion compounds, particularly those able to form nano or micro encapsulation systems. The invention generally refers to inclusion complexes which includes jasmonate compounds.... Agent:

20140220139 - Skin composition for external use containing ceramides: The present invention provides a ceramide lamella structure comprising a glucoside surfactant, a preparation method thereof, and a skin composition for external use containing the same. According to the skin preparation composition for external use of the present invention, phase stability is very excellent and a greater amount of ceramides... Agent: Amorepacific Corporation

20140220136 - System and method for delivering protease inhibitors: The disclosed invention provides a system and method of artificially retarding fibrin-based blood clot degradation via the sustained release of a protease inhibitor, such as, for example, aprotinin or tranexamic acid (“TA”). The sustained release of the protease inhibitor is accomplished through incorporation within a biodegradable polymer microsphere to produce... Agent:

20140220143 - Immune-stimulating photoactive hybrid nanoparticles: Provides is a therapeutic technology that combines the phototoxic and immune-stimulating ability of photodynamic therapy with the widespread effectiveness of the immune system to reduce the viability of such as cancer cells and tumors. The nanoparticle compositions of the disclosure combine an immunostimulant with a photosensitizer using a nanoparticle delivery... Agent:

20140220145 - Method for stimulating retinal response using photoactive devices: An improved method for stimulating electrical activity in an eye is provided. Provided is a technique for implanting small, nanometer-sized photoactive devices into an eye to improve electrical activity within an eye or mitigate degradation of electrical response in damaged eyes.... Agent: The Regents Of The University Of Colorado, A Body Corporate

20140220144 - Orally disintegrating tablet compositions of lamotrigine: The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with... Agent: Aptalis Pharmatech, Inc.

20140220146 - Use of opioid antagonists for treating urinary retention: The invention pertains to the use of opiod antagonists for the treatment of urinary retention.... Agent: Euro-celtique S.a.

20140220147 - Pharmaceutical composition comprising factor vii encapsulated in micelles: The invention relates to a pharmaceutical composition comprising factor VII encapsulated in micelles formed from block copolymer molecules containing (i) a hydrophilic polymer segment consisting of a polyalkylene glycol and (ii) a hydrophobic polymer segment consisting of a polyamino acid, with said polyamino acid comprising exclusively amino acid residues selected... Agent: Laboratoire Francais Du Fractionnement Et Des Biotechnologies

20140220148 - Diaminooxidase-containing pharmaceutical compositions: The present invention relates to pharmaceutical compositions, food supplement compositions and cosmetic compositions comprising diaminooxidase, and to the use thereof.... Agent: Sciotec Diagnostic Technologies Gmbh

20140220149 - Method for prevention and treatment of reflux injury in the aerodigestive tract and laryngopharynx caused by pepsin: A method for treating or preventing disorders, diseases, and symptom of reflux, that is laryngopharyngeal reflux (LPR), in the laryngopharynx caused by pepsin comprises orally administering to the laryngopharynx of a patient an effective amount of cellulose powder. A method for treating or preventing damage to the lining membranes of... Agent: Euphora Ltd.

20140220150 - Integrative fungal solutions for protecting bees and overcoming colony collapse disorder (ccd): methods and compositions: The present invention is based on a plurality of benefits from the extracts of mycelia of individual fungal species, and their mixtures, to provide an armamentarium of defenses from multiple stressors in order to help bees survive and more particularly overcome a complex of symptoms collectively called colony collapse disorder... Agent:

20140220151 - Stability in vitamin and mineral supplements: The invention provides a multivitamin and mineral nutritional supplement composition comprising at least one polyvalent metal and at least one oxidizable vitamin with substantially improved resistance to reactions that lead to darkening and/or spotting and reactions that may reduce the potency of oxidizable vitamins. The composition is a multivitamin and... Agent:

20140220153 - Antimicrobial compositions and uses thereof: The invention is generally directed to antimicrobial composition comprising a matrix material and both of silver and zinc distributed there through, wherein the matrix material comprises at least one of Si02, Ti02, Zr02, AI203, or Zeolite, and the uses of such compositions as anti-bacterial and acaricidal. The invention is also... Agent: Nanox Tecnologia S/a

20140220152 - Compositions and methods for detecting, treating, or preventing reductive stress: Disclosed herein is a non-human animal model of protein aggregation cardiomyopathy. Also disclosed are compositions and methods of treating or preventing a condition in a subject caused or exacerbated by reductive stress. Also disclosed are compositions and methods of predicting, detecting, or monitoring reductive stress in a subject.... Agent: University Of Utah Research Foundation

20140220154 - Method of treating pathologic heterotopic ossification: What is described is a method of preventing or treating heterotopic ossification, vascular calcification, and pathologic mineralization, comprising administering an drug, wherein the drug is an antagonist of the Hedgehog (Hh) pathway. For example the antagonist consists of arsenic trioxide, sodium arsenite, phenylarsine, GANT-58, GANT-61, zerumbone vismodegib (GDC-0449, Genentech), bevacizumab,... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Service

20140220157 - Method of debriding tissue: The present invention relates to ionic compositions for debriding a tissue, particularly in the sinonasal cavity. The ionic components of the composition can include potassium, calcium, rubidium, zinc, bromide, and magnesium in an isotonic solution. In other embodiments, the ionic components of the composition can include magnesium, bromide, sulfate, sodium,... Agent: Red Oax Holdings, LLC

20140220156 - Method of promoting mucosal reciliation: The present invention relates to ionic compositions for promoting mucosal reciliation, particularly in the sinonasal cavity. The ionic components of the composition can include potassium, calcium, rubidium, zinc, bromide, and magnesium in an isotonic solution. In other embodiments, the ionic components of the composition can include magnesium, bromide, sulfate, sodium,... Agent: Red Oax Holdings, LLC

20140220155 - Vaginal tissue rejuvenation compositions and methods: A method of stimulating elastin and/or collagen production in the tissues of the vagina, comprising the steps of providing a composition including at least one of a water soluble zinc salt such as zinc sulfate and a peroxisome proliferator-activated receptor beta/delta (PPAR 13/8) agonist, and administering the composition to the... Agent: University Of Miami

20140220158 - Skin rejuvenation cream: This invention is based upon the discovery that a mixture of ethyl lactate and isoamyl lactate can be used to improve the penetration of active ingredients in skin care formulations through the outer layers of the stratum corneum and viable epidermis and into the dermis layer of the skin structure.... Agent: Ad Lunam Labs Inc.

20140220159 - Hydrogen-bond surrogate peptides and peptidomimetics for p53 reactivation: The present invention relates to peptidomimetics for reactivating p53. Methods of using the peptidomimetics are also disclosed.... Agent:

20140220160 - Method for detecting, quantifying and mapping damage and/or repair of dna strands: Methods and products for detecting in vitro the presence of damage on DNA or the presence of a biological response to damage on DNA at the molecular level. Molecular Combing or other nucleic acid stretching methods are employed together with compounds reacting with DNA, probes binding DNA, or nucleic acid... Agent: Genomic Vision

20140220161 - Compositions and methods to modulate angiogenesis: The present invention provides methods of stimulating angiogenesis and the growth or migration of cells associated with angiogenesis, by contacting animals, tissues, or cells with sulfide, alone or in combination with nitric oxide. These methods may be used for a variety of purposes, including promoting wound healing, increasing blood flow,... Agent: Fred Hutchinson Cancer Research Center

20140220162 - Preparation comprising amino acids and plants and its activity in the alcohol detoxification: The invention relates to a preparation containing several amino acids and plant extracts and its alcohol detoxification activity. The component (a) in the preparation contains a mixture of two or more amino acids or derivatives thereof; the component (b) in the preparation contains a mixture of three or more extracts... Agent: Modutech S.a.

20140220163 - Powder mixture composition of natural materials for controlling deficiencies in polypeptide alpha and beta hemoglobin chains: The embodiments herein provide a powdered composition of natural substances for controlling deficiencies in polypeptide alpha and beta hemoglobin chains and a diet plan for treating thalassemia patient. The composition comprises passargad powder, pars powder, purgative material, fumigation material, snuffing material, vinegar syrup and parsomash powder. The passargad powder is... Agent:

20140220164 - Pest control formulations and methods of making and using same: Compositions useful for controlling pests are disclosed. In some embodiments, the composition includes a pesticidal natural oil and a polar aromatic solvent or an alkyl alcohol solvent. Methods of making and using the compositions are disclosed.... Agent: 0903608 B.c. Ltd.

20140220165 - Compositions for the treatment of peripheral ulcers of various origins: The present invention relates to combinations of an agent that stimulates cell proliferation and an anti-inflammatory/analgesic, which are useful in the treatment of peripheral ulcers of various origins, such as radiation dermatitis, diabetic ulcers, ulcers caused by venous stasis of the limbs, bedsores, and the associated skin infections, proctitis, vulvovaginitis... Agent: Indena S.p.a.

20140220166 - Pharmaceutical composition containing extract of houttuynia cordata as active ingredient for preventing and treating dementia, parkinson's disease, or epilepsy: Pharmaceutical compositions containing an extract of Houttuynia cordata (THUNB) as an active ingredient for preventing and treating dementia, Parkinson's disease, or epilepsy and methods for using the same. Since the extract of Houttuynia cordata or the mixture of the extract of Houttuynia cordata and the extract of Ampelopsis japonica Makino... Agent: University Industry Cooperation Group Of Kyung Hee University

  
  
  
Previous industry: Chemistry of inorganic compounds
Next industry: Plastic article or earthenware shaping or treating: apparatus


######

RSS FEED for 20140807: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 1.13968 seconds

PATENT INFO